FDA Determines Regulatory Review Period for NAMENDA Patent Extension

Summary

The Food and Drug Administration (FDA) has officially announced the regulatory review period for NAMENDA, a human drug product, in accordance with federal regulations. This decision was prompted by patent extension applications submitted to the US Patent and Trademark Office (USPTO) by the pharmaceutical company responsible for NAMENDA.